Central Serous Chorioretinopathy

Raffael Liegl    Michael W. Ulbig

Department of Ophthalmology, Ludwig Maximilian University of Munich, Munich, Germany

Key Words
Central serous chorioretinopathy · Pathogenesis · Epidemiology · Risk factors

Abstract
The pathogenesis of central serous chorioretinopathy (CSC) is still not fully understood. The involvement of corticosteroids is undisputed, although their exact role has not been clarified; other parts of the underlying mechanism of CSC have been mainly elucidated by imaging techniques such as fluorescein and indocyanine green angiography. Even though most cases of CSC are self-limiting, severe as well as recurrent courses exist, and for these patients only a limited number of treatment options are available: laser photocoagulation, with a risk of scotoma and choroidal neovascularization, and photodynamic therapy. In this review article, we give an overview of its epidemiology, the current understanding of its pathogenesis as well as systemic and ocular risk factors. We illuminate modern diagnostic tools as well as current treatment options in the context of CSC, particularly in the light of a better understanding of corticosteroids and their receptors involved in its pathogenesis.

Introduction

In 1866 Albrecht von Graefe [1] described a disease that he referred to as ‘recurrent central retinitis’. Patients suffering from this condition showed a circumscribed serous retinal detachment typically affecting the posterior pole, particularly the macular region (fig. 1). The exact underlying mechanism of that disease was not known in those days, nor is it fully understood today. Von Graefe introduced the idea of retinitis, implying that there was an inflammatory component of this disease, based on his observation that all patients with this condition during that time also suffered from syphilis [2]. Nowadays it has been common to refer to this condition as ‘central serous chorioretinopathy’ (CSC), a term mainly coined by Donald Gass in the late 1960s; however, other synonyms such as ‘(chorio)retinopathia centralis serosa’ or ‘central serous retinopathy’ are also still in use.

The evolution of the term ‘central serous chorioretinopathy’ has always been closely linked to the conception of the pathomechanism underlying this disease at the respective point in time. Horniker [3] was the first to revise von Graefe’s idea of an inflammation as the underlying reason for the disease, as he observed patients with this condition without any previous history of syphilis. Rather, he believed that it was a constitutional angioneurosis which caused vasospasm and subsequent exudation in these patients [3]. Later concepts included Gifford and Marquardt’s [4] ‘central angio- spasitic retinopathy’ in 1939 as they believed an angiopathy with an abnormal vessel muscle tone was the reason for this disorder.

The evolution of the term ‘central serous chorioretinopathy’ has always been closely linked to the conception of the pathomechanism underlying this disease at the respective point in time. Horniker [3] was the first to revise von Graefe’s idea of an inflammation as the underlying reason for the disease, as he observed patients with this condition without any previous history of syphilis. Rather, he believed that it was a constitutional angioneurosis which caused vasospasm and subsequent exudation in these patients [3]. Later concepts included Gifford and Marquardt’s [4] ‘central angio- spasitic retinopathy’ in 1939 as they believed an angiopathy with an abnormal vessel muscle tone was the reason for this disorder.

The concept of a vasospastic disease did not change until fluorescein angiography (FA) was introduced in ophthalmology, allowing a better understanding of the disease. In 1965 Maumenee [5] was the first to publish his
observation on leakage, which he made during FA at the level of the retinal pigment epithelium (RPE), suggesting involvement of both the RPE and the choroid. More detailed observations and a further understanding of the condition, mainly through better-characterized FA findings, finally led to the term ‘idiopathic central serous chorioretinopathy’ by Gass, which over time has been adjusted to ‘central serous chorioretinopathy’ owing to the knowledge about the hyperpermeability of the RPE [6, 7].

In this review article, we give an overview of the epidemiology of CSC, the current understanding of its pathogenesis as well as systemic and ocular risk factors. We illuminate modern diagnostic tools in the context of CSC as well as current treatment options, particularly in the light of a better understanding of corticosteroids and their receptors involved in the pathogenesis.

**Epidemiology**

Although CSC has not been in the focus of research over the last years, clinicians are often confronted with this disease as it is supposed to be the fourth most common nonsurgical retinopathy after age-related macular degeneration, diabetic retinopathy and branch retinal vein occlusion [8]. Historically, its occurrence has mainly been associated with men in their 30s to 40s. Indeed, although only one population-based study and no systemic epidemiologic survey of CSC has been carried out, a large number of single studies support the idea of men being more often affected than women, presenting male-to-female ratios of up to 8:1 [9–14]. The mean age of patients affected is quoted variably in these studies but seems to be slightly higher than usually assumed, with a peak at around 40–45 years in men, although some studies suggest even higher mean ages for men [15–18] and particularly for women and patients with chronic CSC [8, 11, 19]. In addition, cases of CSC in children have been reported [20, 21].

In terms of occurrence among different races, there seems to be a shift in distribution toward people of Hispanic, Asian and Caucasian descent [22, 23]. People of African descent seem to be affected notably less frequently according to some authors, although it has been discussed that this conception might be wrong and derived from the reduced availability of medical infrastructure in poor countries for adequately diagnosing this condition [24]. Some authors also report on more aggressive courses of the disease in Black people [25, 26].

**Pathogenesis**

CSC has long been considered to be a vasospastic disease. This conception has been largely abandoned with the advent of diagnostic imaging techniques such as FA and indocyanine green angiography (ICGA). However, its pathogenesis still remains unclear in spite of these advances. Numerous hypotheses have been proclaimed and mainly involve the RPE as well as the choroid as being central contributors to subretinal fluid accumulation with subsequent detachment of the neurosensory retina [27].

The current idea of the pathophysiology of CSC mainly proclaims choroidal vascular hyperpermeability to be the major reason for the increased tissue hydrostatic pressure beneath the RPE that can eventually lead to disintegration of the continuity of the RPE [28]. The observation that the retinal detachment regresses once the fluorescein leakage from one or multiple sites stops, as found by FA, has been interpreted as showing that there was a lesion of the RPE leading to subretinal accumulation of fluid originating from the choroid [16, 29]. ICGA findings show a staining of the inner choroid in the midphase of the angiogram, suggesting choroidal vascular hyperpermeability which may arise from venous congestion and ischemia [30–35]. Under physiologic conditions, the balance between oncotic and hydrostatic pressure usually leads to fluid flowing from the retina toward the choroid [16]. In
CSC, however, an extensive hydrostatic pressure within the choroid leads to fluid being squeezed out of the choroidal vascular system and subsequently accumulating underneath the RPE [36, 37]. Once the tissue hydrostatic pressure beneath the RPE is high enough, it is believed that it pushes the RPE forward, which in turn results in discontinuity of the RPE barrier, leading to pigment epithelial detachment (PED) and pinpoint areas of leakage often referred to as ‘microrips’ or ‘blowouts’ [38, 39]. In addition, the damage to the RPE is presumed to lead to an aggravation of this condition, since the RPE may be restricted in its ability to pump fluid out of the subretinal space. This theory is further supported by the clinical finding of leaks in the RPE demonstrated by FA at the level of choroidal vascular hyperpermeability [40, 41]. However, choroidal thickening as seen by OCT and inner choroidal staining as signs of increased choroidal hyperpermeability can also be observed in other regions of the retina not directly adjacent to a PED or microrip. Although this might counteract the idea of a PED caused by fluid pushing from the choroid toward the RPE, one explanation includes the typical area of clinically observed PED in the foveal region with presumably weaker attachment of the thinner retina and therefore greater predisposition to serous retinal detachment [8].

The role of the RPE is still only vaguely understood and other ideas of the pathophysiology of CSC also include an abnormal polarity of some of the RPE cells leading to fluid being pumped from the choroid to the retina [42]. This concept, however, has some weaknesses as it fails to explain the occurrence of PED and why some depolarized RPE cells overwhelm the surrounding, normally aligned RPE cells in terms of fluid flow direction.

The mechanistic hypothesis proposing that fluid coming from hyperpermeable choroidal vessels leads to increased tissue hydrostatic pressure – which results in RPE damage – seems reasonable; however, it does not explain why the choroidal vascular system would develop an increased permeability.

Systemic and Ocular Risk Factors

Several risk factors for the development of CSC exist, but they are not fully understood, and only high serum glucocorticoid levels seem to be unambiguously related to the occurrence of CSC [18, 43]. Increased glucocorticoid and serum catecholamine levels have been found in patients with CSC [12, 44–47]. However, no increased risk for the development of CSC has been observed after intake of sympathomimetic agents alone [27]. Furthermore, no improvement in the course of CSC was seen after intake of β-blockers, suggesting that the simultaneous upregulation of serum catecholamine levels in a situation of increased glucocorticoid levels is due to a stress response, rather than suggesting that the disease triggers this increased expression [48, 49]. With respect to corticosteroids, however, several studies proved an association of increased levels with CSC for corticosteroids of endogenous and particularly exogenous origin [50, 51]. Glucocorticoid as well as mineralocorticoid hormones belong to the same group referred to as corticosteroids synthesized from cholesterol. It is well known that corticosteroids have an impact on the RPE, Bruch’s membrane and the choriocapillaris, possibly altering their permeability directly or secondarily due to vascular autoregulation or vascular reactivity [52–54]. It remains unclear, though, why elevated serum corticosteroid levels may trigger CSC, while intraocular injections of triamcinolone or similar drugs are very rarely associated with the development of CSC [16, 55, 56].

One of the first risk factors identified was having a type A personality [23]. People referred to as having a type A personality are usually characterized by a highly status-conscious, ambitious and rigidly organized pattern of behavior [57]. Further risk factors that have been proposed include pregnancy, alcohol consumption, untreated hypertension, use of antibiotics, bone marrow or organ transplantation, infection of the respiratory tract and infection with Helicobacter pylori [12, 44, 58–63].

Clinical Presentation

CSC typically occurs unilaterally in younger patients and is characterized by decreased and distorted vision, often associated with metamorphopsia, micropsia, mild dyschromatopsia and reduced contrast sensitivity [64]. However, bilateral affection occurs and is more often seen in elderly patients.

CSC can occur in an acute or chronic form, but no generally accepted duration has been defined for the chronic form; many authors tend to speak of chronic CSC if symptoms last longer than 3 months, but other authors speak of chronicity if CSC alterations and symptoms are present for more than 6 months [65–67]. Visual acuity is usually reduced to 20/30 to 20/60 and can in some cases be corrected with a weak plus lens due to a slightly elevated retina level causing mild hypermetropia [16, 64]. While acute CSC usually resolves spontaneously with re-
turn to normal or almost normal visual acuity, recurrent forms are not rare and may be seen in more than 50% of patients suffering from CSC [68, 69]. Clinically, it most commonly presents as a localized, circumscribed area of retinal detachment most often in the macular region. The subretinal fluid is usually clear in acute cases but may also have a hazy or fibrinous appearance, while additional blood is very uncommon in CSC. The RPE may show areas of disturbance or abnormal pigmentation variable in size within the detachment of the sensory retina, sometimes even leading to PED.

Chronic CSC, on the other hand, typically goes along with more advanced stages of RPE alteration, which my lead to a distinct and permanent loss of visual acuity. This form has also been termed ‘diffuse retinal pigment epitheliopathy’ and implies an advanced age at the time of the diagnosis [17]. Detachments of the neurosensory retina in these patients differ from those in patients with acute CSC as they appear less elevated and may show thinning of the retina as well as atrophy of the underlying RPE. The prolonged detachment may be caused by photoreceptor and RPE damage and results in unfavorable visual acuity; moreover, a minority of cases might even develop choroidal neovascularization (CNV) and RPE tears with subsequent risk of severe visual impairment [70, 71].

Another form of CSC is characterized by large, usually multiple, sectors of bullous, serous retinal and/or RPE detachments. It is a rare form and may occur secondary to CSC. Typical features include greater numbers and sizes of areas of choroidal hyperpermeability and bullous retinal detachment which often extends by gravitation to the inferior part of the retina. It seems to be more frequent in Japanese people and has been reported after organ transplantation as well [72–74].

Imaging in CSC

Imaging techniques such as FA or ICGA have been very helpful tools for gaining a better understanding of the pathophysiology of CSC and for supporting a diagnosis of CSC. However, a better knowledge of risk factors and patient characteristics as well as gradual improvements in clinical description have led to the situation that most CSC cases can be sufficiently diagnosed without further need for imaging devices. Apart from invasive imaging tools such as FA and ICGA, novel developments including OCT with enhanced depth imaging and fundus autofluorescence imaging (FAF) may contribute to a deeper understanding of the disease.

**Fluorescein Angiography**

Angiographic findings for acute CSC are characterized by focal fluorescein leaks at the level of the RPE leading to subretinal accumulation of dye [75]. Three different manifestations have been described and include ‘smokestack leak’ and ‘inkblot leak’ patterns (fig. 2),

![Fig. 2. Widefield angiography of the right eye of a 42-year-old male patient with typical inkblot leakage 30 s after fluorescein injection (a) and 5 min later (b). No other leakages could be detected in this patient, but leakages in the periphery even of asymptomatic eyes are not uncommon.](image-url)
depending on the nature of the protein in the subretinal fluid and the morphology of the altered RPE [76, 77].

A ‘smokestack leak’ is associated with pinpoint focal RPE leaks and present in only 7% of patients suffering from CSC. The majority (approx. 93%) has a more uniform dye spread also referred to as an ‘inkblot leak’. These pinpoint areas of hyperfluorescence tend to expand in the time course of the FA in a roundish fashion. The leakage points, regardless of their pattern, are usually distributed in a 1-mm-wide ring-shaped zone starting 0.5 mm from the center of the fovea. More than half of the leakages are found in the nasal quadrant, followed by the temporal quadrant, with approximately 35% of the leakages located there [9, 16, 76].

**Indocyanine Green Angiography**

In CSC an inner choroidal staining can typically be appreciated as a possible sign of fibrin. This staining appears in the midphase of the ICGA and fades in the late phase, which allows for differentiation from CNV [32, 34]. ICGA is particularly helpful in chronic CSC patients as it is often very difficult to interpret areas of leakage on FA images, and sometimes even patients with no signs of fluorescein leakage show increased choroidal vascular hyperpermeability; however, ICGA usually does not contribute to treatment considerations, although some authors suggest the use of ICGA-guided photodynamic therapy (PDT) [78–81].

**Optical Coherence Tomography**

Spectral-domain OCT (SD-OCT) is a helpful tool in retinal diseases and also in CSC [82]. As a noninvasive diagnostic device, it allows to capture fast and high-resolution sectional images of the retina. Several aspects of CSC have been investigated using OCT: it has been shown that the diameter of the choroidal vessels was significantly wider in affected eyes than in normal control eyes [83]. Other groups showed differences in the architecture of the retinal area involved between acute and chronic CSC, implying that acute CSC patients have a significantly higher pure retinal layer volume but do not differ from chronic patients in terms of subretinal fluid [84]. Furthermore, enhanced depth imaging, a new development of OCT, has provided a deeper insight into choroidal thickness. Several groups were able to prove that the choroid is thicker in patients suffering from CSC in both the affected and the fellow eye compared with normal controls, strengthening the original idea of a hyperpermeable choroid [85–88]. Other OCT findings include photoreceptor elongation as well as other defects in the inner segment/outer segment band which may correlate with visual acuity prognosis [89–91] (fig. 3–5).
Fundus Autofluorescence Imaging

The RPE has been thoroughly evaluated in different diseases and its role in the pathology of CSC seems to be indisputable [92–94]. This perception has been fortified by FAF findings. Due to the anatomic features of the RPE, detailed examination and imaging have been a challenge for many years. The introduction of FAF gave clinical ophthalmologists a sophisticated tool for evaluating RPE changes (fig. 6). Excitation of the RPE, and specifically of lipofuscin, with light of specific wavelengths provokes a characteristic fluorescence [95–97]. Lipofuscin is a metabolite that develops during the depletion of aged outer photoreceptors and accumulates in the RPE [98]. Although lipofuscin, among many other fluorophores,
been supposed to have the strongest impact on retinal autofluorescence, newer studies could show that, particularly in CSC, even precursors of lipofuscin that had not already accumulated in the RPE and were still beneath the neurosensory retina might contribute to the autofluorescence observed in CSC [99].

Typical FAF patterns seen in acute CSC include increased autofluorescence at the site of leakage, probably indicating an increased activity of the RPE as a response to augmented volumes of subretinal fluid [100]. On the other hand, severe hypoautofluorescence – often associated with descending tracts that are surrounded by somewhat hyperautofluorescent borders as a sign of RPE dysfunction or atrophy – is appreciated particularly in chronic cases [99, 101].

Treatment

The course of the different pathogenic concepts of this disease is well reflected by the vast number of different treatment options that have been evaluated and proposed for CSC over time. These include observation and discontinuation of corticosteroids, laser approaches such as PDT, selective retinal therapy (SRT) and standard laser photocoagulation, intravitreal injections of anti-VEGF drugs and several systemic medications including carbonic anhydrase inhibitors, β-blockers and particularly aldosterone antagonists. However, even today, no therapy of CSC may be deemed to be the gold standard, although some therapies provide better evidence for their efficiency than others; thus, of the large number of therapies suggested, only a few can be recommended.

As CSC is, in most cases, self-limiting with spontaneous resolution of the subretinal fluid, observation without additional treatment for the first 3 months is usually an appropriate first approach to handling this disease in patients without exogenous corticosteroid intake and no specific wish to accelerate the healing process. If possible, and after consulting the responsible physician, further management of risk factors includes discontinuation of steroids in patients taking these for other reasons, as well as reduction and avoidance of stress. In cases of chronicity or recurrence, however, other treatment options should be considered.

Photodynamic Therapy

Over the last couple of years, several groups have investigated a possible effect of PDT on CSC with beneficial results in terms of visual acuity and morphologic reconstitution [66, 80, 81, 102–105]. PDT is usually performed by administering 6 mg/m² verteporfin (Visudyne; Novartis Pharma) intravenously and subsequent activation of this dye by a laser light of 689 nm wavelength at a (full) fluence of 50 J/cm². The mechanism of action is postulated to include short-term choriocapillaris hypoperfusion and long-term choroidal vascular...
remodeling with subsequent reduction of vascular hyperpermeability and leakage [65, 102]. Some side effects including RPE alterations, CNV and choroidal ischemia have been reported [106]. In order to reduce these side effects, two modifications to conventional full-dose/fluence PDT have been proposed: (1) half-dose PDT in which the amount of verteporfin is reduced to 3 mg/m² with the same level of laser fluence (50 J/cm²) or (2) half-fluence PDT with the same concentration of verteporfin (6 mg/m²) but with only 25 J/cm² of laser fluence. Both approaches yielded favorable results in terms of visual acuity recovery as well as subretinal fluid resolution in a large number of studies with fewer side effects compared with conventional PDT [65, 81]. In respect of modality, significantly more studies have been carried out to evaluate half-dose PDT and only a few to investigate half-fluence PDT. Half-dose PDT is concordantly regarded as being just as effective as full-dose PDT and is therefore recommended in cases of recurrent or chronic CSC, particularly without severe PED [107–109]. Some authors even recommend it in acute cases with symptoms lasting less than 3 months [110]. Compared with laser photocoagulation, half-dose PDT may also facilitate an earlier resolution of macular detachment and the recovery of central retinal function [111]. One group studied even lower doses of verteporfin but obtained inferior results with one-third-dose PDT compared with half-dose PDT in terms of subretinal fluid resolution [112].

Selective Retinal Therapy

In contrast to standard laser photocoagulation, SRT is supposed to apply laser spots only to the RPE without risk of scotoma by damaging the neurosensory retina [113, 114]. SRT is performed with a Q-switched, frequency-doubled Nd:YLF laser beam with a wavelength of 527 nm [115]. This selective treatment of the RPE is meant to trigger the regeneration of the RPE and a long-term metabolic increase at the chorioretinal junction [116]. Three different studies and case series have been carried out to evaluate the effect of SRT in the setting of CSC [115, 117, 118]. However, all of them were conducted by the same group. A first case series in 2006, comprising 5 patients, showed promising preliminary results in terms of subretinal fluid regression with coexistent PED without any cases of RPE rips [115]. In the same year, another study with 27 patients could also show a very high subretinal fluid regression rate. It must be noted, though, that one third of these patients were treated in the first 3 months after the diagnosis of CSC. In general, these patients also showed final results superior to those of the other study participants, but a tendency toward spontaneous regression cannot be evaluated [117]. In the third study, published in 2011, Klatt et al. [115] confirmed the previous results. Due to the low number of patients (n = 30) included, however, a larger prospective clinical trial is warranted to prove these findings. SRT is currently not commercially available, nor do the results so far prove sufficient effects in the treatment of CSC; therefore, SRT may be a promising treatment option in the future, but further studies are needed.

Laser Photocoagulation

As in other retinal diseases such as clinically significant macular edema in diabetic patients, laser spots are administered to focal leakages that have been identified by FA. The exact mechanism of laser photocoagulation is not known but may be based on sealing of leaking vessels as well as activation of the pumping function of the RPE. Several studies have been carried out to evaluate the role of laser photocoagulation in CSC and good evidence exists that photocoagulation leads to faster resolution of subretinal fluid [68, 103, 119, 120]. However, several studies showed that, in spite of faster subretinal fluid resolution, no significant impact on final visual acuity can be expected [13, 119, 121]. Unlike SRT, standard photocoagulation has also been proposed for chronic cases of CSC and diffuse retinal pigment epitheliopathy but does not have any effect on bullous retinal detachment, a rare form of CSC [27, 122]. Laser photocoagulation, however, needs thorough planning and careful execution and no laser spots should be applied to very central lesions; furthermore, long-term follow-up is necessary to detect cases of CNV, a rare but severe side effect.

Although laser photocoagulation has proved its general potency in CSC, possible side effects, particularly scotoma and the development of CNV, must be considered; therefore, laser photocoagulation should be mainly discussed for patients with long-standing CSC, possibly refractory to other treatment approaches, or with a history of CSC in the fellow eye with an unfavorable visual acuity outcome.

Carbonic Anhydrase Inhibitors

Prescription of oral acetazolamide is a widespread treatment option in CSC in spite of poor evidence in terms of outcome. Only one smaller case study and one prospective nonrandomized trial have been carried out to evaluate the influence of acetazolamide on the course of
CSC. While Gonzalez [123] could show a reduction of metamorphopsia and at least stabilization of visual acuity in a few patients, Pikkel et al. [124] could show that acetazolamide may shorten the subjective as well as objective time of clinical resolution but has no influence on final visual acuity prognosis or recurrence rates.

**Mineralocorticoid Receptor Antagonists**

The exact mode of action of glucocorticoids in the pathogenesis of CSC is still not known, even though their prominent role is beyond controversy. It therefore seems obvious that one should search for treatment options targeting this track. Glucocorticoids bind to their receptor but also to the mineralocorticoid receptor (MR) that belongs to the same family. MR are present in the kidney and the vasculature and were recently demonstrated to be expressed in different cell types of the neurosensory retina [125]. Based on the observation of CSC aggravation by glucocorticoids and the known affinity of glucocorticoids for MR, Zhao et al. [126] hypothesized a potential inappropriate/excessive binding of glucocorticoids to MR and proved their assumption in a rat model. Rat eyes received intravitreal injections of the glucocorticoid corticosterone. OCT before and after injection revealed significantly increased choroidal thickening but no thickening of retinal vessels after 24 h, a finding similar to CSC. The effect of this glucocorticoid may have been triggered by glucocorticoid receptors or MR; therefore, other rats received intravitreal injections of aldosterone, which specifically binds to MR. In these rats, the same effects in terms of choroidal thickening were noticed and therefore an important role of MR deduced. Hence, treatment with an MR antagonist was proposed, and 2 patients with chronic nonresolved CSC were treated with oral eplerenone for 5 weeks. A rapid resolution of the retinal detachment and choroidal vasodilation as well as improvement in visual acuity was observed in these 2 patients, and consequently a larger study followed. This nonrandomized pilot study included 13 patients with chronic CSC (>3 months) treated with 25 mg/day of oral eplerenone for a week followed by 50 mg/day for 1 month or 3 months; it was published in 2013 by Bouquet et al. [127]. All patients showed a significant decrease in central macular thickness at 1 month and 3 months under eplerenone treatment. Overall, not only a decrease in subretinal fluid but also an improvement in visual acuity was observed [127]. Nevertheless, further randomized trials are necessary to prove these conclusions.

**Conclusions**

CSC is a clinical picture that ophthalmologists are frequently confronted with. The therapeutic options are limited, although observation, reduction of stress and discontinuation of corticosteroids, where applicable, are often sufficient to overcome visual deterioration. Still, 40–50% of patients suffer from recurrent forms of CSC, and as for chronic CSC patients, less favorable results in terms of visual acuity and morphologic reconstitution can be expected for these patients. In these cases, the only therapies with good evidence for their efficiency are laser photocoagulation and PDT. Laser photocoagulation carries a risk of severe side effects including CNV and scotoma; PDT shows a lower risk of these but is associated with a high financial burden and therefore not available for every patient.

The first results of a study investigating MR antagonists are promising and agree with our own observations on CSC patients treated with spironolactone, another MR antagonist. MR antagonists such as eplerenone or spironolactone are relatively old drugs mainly used for cardiovascular conditions such as hypertension. The most common side effect is increased urinary frequency; other side effects are rare but include dry skin, rashes and gynecomastia.

Although further studies are needed to prove the value of MR antagonists in the treatment of CSC, from our perspective – against the background of the relatively small side effects of MR antagonists and very limited treatment options – it seems to be appropriate to recommend MR antagonists for patients suffering from CSC without signs of resolution within the first 8–12 weeks.

**Disclosure Statement**

None.

**References**

18 Tsai DC, Chen SJ, Huang CC, Chou P, Chung
11 Wang M, Sander B, la Cour M, Larsen M:
17 Spaide RF, Campeas L, Haas A, Yannuzzi LA,
16 Spaide RF: Central serous chorioretinopathy;
20 Kim YC, Kim SD, Kim KS: A case of idiopath-
14 Jamil AZ, Mirza KA, Qazi ZU, Iqbal W,
15 Kitzmann AS, Pulido JS, Diehl NN, Hodge
5 Maumenee AE: Macular diseases: clinical
10 Castro-Correia J, Coutinho MF, Rosas V,
8 Wang M, Munch IC, Hasler PW, Prünte C,
7 Meyerle CB, Spaide RF: Central serous cho-
6 Gass JD: Pathogenesis of disciform detach-
529–533.
51 Garg SP, Dada T, Talwar D, Biswas NR: En-
46 Thoelen AM, Bernasconi PP, Schmid C,
43 Bouzas EA, Karadimas P, Pournaras CJ: Cen-
39 Goldstein BG, Pavan PR: ‘Blow-outs’ in the
38 Slakter JS, Sander JA, Orlock DA: Indocyanine-green angiogra-
37 Slakter JS, Yannuzzi LA, Guyer DR, Sorenson
35 Scheider A, Nasemann JE, Lund OE: Fluores-
34 Guyer DR, Slakter JS, Sorenson JA, Orlock DA: Indocyanine-green angiogra-
33 Slakter JS, Yannuzzi LA, Guyer DR, Sorenson
32 Spaide RF, Hall L, Haas A, Yannuzzi LA, Fisher
31 Prünte C, Flammer J: Choroidal capillary and
30 Okushiba U, Takeda M: Study of choroidal
29 Yannuzzi LA: Central serous chorioretinopa-
28 Uyama M, Matsunaga H, Matsubara T, Fuku-
27 Nicholson B, Noble J, Forooghian F, Meyerle
26 Desai UR, Alhalel AA, Campen TJ, Schiffman
25 Balo KP, Mihluedo H: Idiopathic central se-
24 Balo KP, Mihluedo H: Idiopathic central se-
23 Balo KP, Mihluedo H: Idiopathic central se-
22 Balo KP, Mihluedo H: Idiopathic central se-
21 Alwassia AA, Adhi M, Duker JS: Bilateral si-
20 Kim YC, Kim SD, Kim KS: A case of idiopath-
19 Yannuzzi LA: Type-A behavior and central serous chorioretinopathy: Retina 1987;7:111–
18 Balo KP, Mihluedo H: Idiopathic central se-
17 Spaide RF, Campeas L, Haas A, Yannuzzi LA,
16 Spaide RF: Central serous chorioretinopathy;
15 Kitzmann AS, Pulido JS, Diehl NN, Hodge
14 Jamil AZ, Mirza KA, Qazi ZU, Iqbal W,
13 Gilbert CM, Owens SL, Smith PD, Fine SL:
12 Tittl MK, Spaide RF, Wong D, Pilottto E, Yan-
11 Wang M, Sander B, la Cour M, Larsen M:
10 Castro-Correia J, Coutinho MF, Rosas V,
9 Wang M, Munch IC, Hasler PW, Prünte C,
8 Wang M, Munch IC, Hasler PW, Prünte C,
7 Meyerle CB, Spaide RF: Central serous cho-
6 Gass JD: Pathogenesis of disciform detach-
5 Maumenee AE: Macular diseases: clinical
4 Gass JD: Pathogenesis of disciform detach-
3 Slakter JS, Yannuzzi LA, Guyer DR, Sorenson
2 Slakter JS, Yannuzzi LA, Guyer DR, Sorenson
1 Meyerle CB, Spaide RF: Central serous cho-
DOI: 10.1159/000360014
Central Serous Chorioretinopathy

Ophthalmologica 2014;232:65–76
DOI: 10.1159/000360014


